{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T05:56:23Z","timestamp":1781157383612,"version":"3.54.1"},"reference-count":93,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.hoc.2026.03.001","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:05:06Z","timestamp":1781136306000},"page":"331-346","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Updates in Childhood Acute Lymphoblastic Leukemia"],"prefix":"10.1016","volume":"40","author":[{"given":"Sara","family":"Zarnegar-Lumley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"McNeer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.hoc.2026.03.001_bib1","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.blre.2012.01.001","article-title":"The clinical relevance of chromosomal and genomic abnormalities in B-cell precursor acute lymphoblastic leukaemia","volume":"26","author":"Moorman","year":"2012","journal-title":"Blood Rev"},{"issue":"9","key":"10.1016\/j.hoc.2026.03.001_bib2","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1182\/blood-2014-03-562918","article-title":"A novel integrated cytogenetic and genomic classification refines risk stratification in pediatric acute lymphoblastic leukemia","volume":"124","author":"Moorman","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2026.03.001_bib3","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1365-2141.2008.07417.x","article-title":"Cytogenetics of paediatric and adolescent acute lymphoblastic leukaemia","volume":"144","author":"Harrison","year":"2009","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.hoc.2026.03.001_bib4","first-page":"4036","article-title":"Hypodiploidy with less than 45 chromosomes confers adverse risk in childhood acute lymphoblastic leukemia: a report from the children\u2019s cancer group","volume":"94","author":"Heerema","year":"1999","journal-title":"Blood"},{"issue":"27","key":"10.1016\/j.hoc.2026.03.001_bib5","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1200\/JCO.2013.49.1308","article-title":"Intrachromosomal amplification of chromosome 21 is associated with inferior outcomes in children with acute lymphoblastic leukemia treated in contemporary standard-risk children\u2019s oncology group studies: a report from the children\u2019s oncology group","volume":"31","author":"Heerema","year":"2013","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2026.03.001_bib6","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/j.1365-2141.2004.04948.x","article-title":"Three distinct subgroups of hypodiploidy in acute lymphoblastic leukaemia","volume":"125","author":"Harrison","year":"2004","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.hoc.2026.03.001_bib7","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/leu.2013.317","article-title":"An international study of intrachromosomal amplification of chromosome 21 (iAMP21): cytogenetic characterization and outcome","volume":"28","author":"Harrison","year":"2014","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.hoc.2026.03.001_bib8","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1182\/blood-2006-08-040436","article-title":"Prognosis of children with acute lymphoblastic leukemia (ALL) and intrachromosomal amplification of chromosome 21 (iAMP21)","volume":"109","author":"Moorman","year":"2007","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2026.03.001_bib9","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3324\/haematol.2015.141101","article-title":"New and emerging prognostic and predictive genetic biomarkers in B-cell precursor acute lymphoblastic leukemia","volume":"101","author":"Moorman","year":"2016","journal-title":"Haematologica"},{"issue":"25","key":"10.1016\/j.hoc.2026.03.001_bib10","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1200\/JCO.19.00261","article-title":"Outcome of infants younger than 1 year with acute lymphoblastic leukemia treated with the Interfant-06 protocol: results from an international phase III randomized study","volume":"37","author":"Pieters","year":"2019","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2026.03.001_bib11","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1182\/blood-2018-04-785980","article-title":"How I treat infant leukemia","volume":"133","author":"Brown","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2026.03.001_bib12","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1200\/JCO.1996.14.1.18","article-title":"Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia","volume":"14","author":"Smith","year":"1996","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.hoc.2026.03.001_bib13","doi-asserted-by":"crossref","first-page":"5477","DOI":"10.1182\/blood-2008-01-132837","article-title":"Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children\u2019s Oncology Group study","volume":"111","author":"Borowitz","year":"2008","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.hoc.2026.03.001_bib14","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1182\/blood-2015-03-633685","article-title":"Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children\u2019s Oncology Group study AALL0232","volume":"126","author":"Borowitz","year":"2015","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.hoc.2026.03.001_bib15","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1182\/blood-2009-10-248146","article-title":"Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study","volume":"115","author":"Conter","year":"2010","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2026.03.001_bib16","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1056\/NEJMoa0808253","article-title":"Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia","volume":"360","author":"Mullighan","year":"2009","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.hoc.2026.03.001_bib17","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S1470-2045(08)70339-5","article-title":"A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study","volume":"10","author":"Den Boer","year":"2009","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.hoc.2026.03.001_bib18","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa1403088","article-title":"Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia","volume":"371","author":"Roberts","year":"2014","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.hoc.2026.03.001_bib19","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1182\/blood-2016-12-758979","article-title":"Targetable kinase gene fusions in high-risk B-ALL: a study from the Children\u2019s Oncology Group","volume":"129","author":"Reshmi","year":"2017","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.hoc.2026.03.001_bib20","doi-asserted-by":"crossref","first-page":"e114","DOI":"10.1016\/j.leukres.2011.02.011","article-title":"The t(1;9)(p34; q34) fusing ABL1 with SFPQ, a pre-mRNA processing gene, is recurrent in acute lymphoblastic leukemias","volume":"35","author":"Duhoux","year":"2011","journal-title":"Leuk Res"},{"issue":"2","key":"10.1016\/j.hoc.2026.03.001_bib21","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ccr.2012.06.005","article-title":"Genetic alterations activating kinase and cytokine receptor signaling in highrisk acute lymphoblastic leukemia","volume":"22","author":"Roberts","year":"2012","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.hoc.2026.03.001_bib22","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1111\/bjh.13757","article-title":"Identification of novel kinase fusion transcripts in paediatric B cell precursor acute lymphoblastic leukaemia with IKZF1 deletion","volume":"171","author":"Yano","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2026.03.001_bib23","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2016.28","article-title":"Characterization of pediatric Philadelphia-negative B-cell precursor acute lymphoblastic leukemia with kinase fusions in Japan","volume":"6","author":"Imamura","year":"2016","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.1016\/j.hoc.2026.03.001_bib24","doi-asserted-by":"crossref","first-page":"4618","DOI":"10.18632\/oncotarget.13492","article-title":"Tyrosine kinase fusion genes in pediatric BCR-ABL1-like acute lymphoblastic leukemia","volume":"8","author":"Boer","year":"2017","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.hoc.2026.03.001_bib25","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1200\/JCO.2016.69.0073","article-title":"High frequency and poor outcome of Philadelphia chromosome-like acute lymphoblastic leukemia in adults","volume":"35","author":"Roberts","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2026.03.001_bib26","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms13331","article-title":"Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia","volume":"7","author":"Gu","year":"2016","journal-title":"Nat Commun"},{"issue":"19","key":"10.1016\/j.hoc.2026.03.001_bib27","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1182\/blood-2017-06-743252","article-title":"Philadelphia chromosome-like acute lymphoblastic leukemia","volume":"130","author":"Tasian","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2026.03.001_bib28","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1182\/bloodadvances.2019000163","article-title":"Clinical diagnostics and treatment strategies for Philadelphia chromosome-like acute lymphoblastic leukemia","volume":"4","author":"Harvey","year":"2020","journal-title":"Blood Adv"},{"issue":"31","key":"10.1016\/j.hoc.2026.03.001_bib29","doi-asserted-by":"crossref","first-page":"5175","DOI":"10.1200\/JCO.2008.21.2514","article-title":"Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children\u2019s oncology group study","volume":"27","author":"Schultz","year":"2009","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.hoc.2026.03.001_bib30","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/leu.2014.30","article-title":"Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: children\u2019s oncology group study AALL0031","volume":"28","author":"Schultz","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2026.03.001_bib31","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.10006","article-title":"Outcomes of dasatinib plus intensive chemotherapy or stem cell transplant for philadelphia chromosome-positive acute lymphoblastic leukemia on children\u2019s oncology group AALL0622","volume":"33","author":"Slayton","year":"2015","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2026.03.001_bib32","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/leu.2016.375","article-title":"High incidence of Philadelphia chromosome-like acute lymphoblastic leukemia in older adults with B-ALL","volume":"31","author":"Tasian","year":"2017","journal-title":"Leukemia"},{"issue":"25","key":"10.1016\/j.hoc.2026.03.001_bib33","doi-asserted-by":"crossref","first-page":"e413","DOI":"10.1200\/JCO.2012.47.6770","article-title":"Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia","volume":"31","author":"Weston","year":"2013","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.hoc.2026.03.001_bib34","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.3324\/haematol.2013.095372","article-title":"Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion","volume":"98","author":"Lengline","year":"2013","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.hoc.2026.03.001_bib35","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1002\/pbc.25327","article-title":"TKI dasatinib monotherapy for a patient with Ph-like ALL bearing ATF7IP\/PDGFRB translocation","volume":"62","author":"Kobayashi","year":"2015","journal-title":"Pediatr Blood Cancer"},{"issue":"17","key":"10.1016\/j.hoc.2026.03.001_bib36","doi-asserted-by":"crossref","first-page":"3510","DOI":"10.1182\/blood-2012-03-415448","article-title":"Targeting JAK1\/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia","volume":"120","author":"Maude","year":"2012","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2026.03.001_bib37","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ccell.2015.12.013","article-title":"Truncating erythropoietin receptor rearrangements in acute lymphoblastic leukemia","volume":"29","author":"Iacobucci","year":"2016","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/j.hoc.2026.03.001_bib38","doi-asserted-by":"crossref","first-page":"e427","DOI":"10.3324\/haematol.2018.192088","article-title":"Clinical efficacy of ruxolitinib and chemotherapy in a child with Philadelphia chromosome-like acute lymphoblastic leukemia with","volume":"103","author":"Ding","year":"2018","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.hoc.2026.03.001_bib39","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1182\/blood-2016-05-707653","article-title":"Potent efficacy of combined PI3K\/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia","volume":"129","author":"Tasian","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2026.03.001_bib40","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ccell.2015.06.005","article-title":"Activity of the type II JAK2 inhibitor CHZ868 in B cell acute lymphoblastic leukemia","volume":"28","author":"Wu","year":"2015","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.hoc.2026.03.001_bib41","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1158\/1535-7163.MCT-14-0647","article-title":"Evaluation of the in vitro and in vivo efficacy of the JAK inhibitor AZD1480 against JAK-mutated acute lymphoblastic leukemia","volume":"14","author":"Suryani","year":"2015","journal-title":"Mol Cancer Therapeut"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2026.03.001_bib42","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1182\/blood-2023-190495","article-title":"Feasibility and outcome of post-induction therapy incorporating dasatinib for patients with newly diagnosed ABL-class fusion B-Lymphoblastic leukemia (ABL-class Fusion B-ALL): children\u2019s oncology group AALL1131","volume":"142","author":"Salzer","year":"2023","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2026.03.001_bib43","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1002\/ajh.26908","article-title":"High response rates and transition to transplant after novel targeted and cellular therapies in adults with relapsed\/refractory acute lymphoblastic leukemia with Philadelphia-like fusions","volume":"98","author":"Aldoss","year":"2023","journal-title":"Am J Hematol"},{"issue":"17","key":"10.1016\/j.hoc.2026.03.001_bib44","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa2016272","article-title":"Dasatinib-blinatumomab for Ph-Positive acute lymphoblastic leukemia in adults","volume":"383","author":"Fo\u00e0","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.hoc.2026.03.001_bib45","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1016\/S2352-3026(22)00319-2","article-title":"Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial","volume":"10","author":"Jabbour","year":"2023","journal-title":"Lancet Haematol"},{"issue":"36","key":"10.1016\/j.hoc.2026.03.001_bib46","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.1200\/JCO.24.00272","article-title":"Results of the simultaneous combination of ponatinib and blinatumomab in Philadelphia chromosome-positive ALL","volume":"42","author":"Kantarjian","year":"2024","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.hoc.2026.03.001_bib47","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1182\/bloodadvances.2022008216","article-title":"Dasatinib\/prednisone induction followed by blinatumomab\/dasatinib in Ph+ acute lymphoblastic leukemia","volume":"7","author":"Advani","year":"2023","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2026.03.001_bib48","doi-asserted-by":"crossref","first-page":"6117","DOI":"10.1182\/blood-2022-164699","volume":"140","author":"Tasian","year":"2022","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.hoc.2026.03.001_bib49","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2018-10-881961","article-title":"A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403","volume":"133","author":"Stock","year":"2019","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2026.03.001_bib50","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1038\/s41588-022-01159-z","article-title":"The genomic landscape of pediatric acute lymphoblastic leukemia","volume":"54","author":"Brady","year":"2022","journal-title":"Nat Genet"},{"issue":"9","key":"10.1016\/j.hoc.2026.03.001_bib51","first-page":"1951","article-title":"KMT2A-rearranged acute lymphoblastic leukemia in infants: current progress and challenges","volume":"110","author":"Stutterheim","year":"2025","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.hoc.2026.03.001_bib52","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.cell.2005.09.025","article-title":"The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis","volume":"123","author":"Yokoyama","year":"2005","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.hoc.2026.03.001_bib53","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.ccell.2019.11.001","article-title":"A Menin-MLL inhibitor induces specific chromatin changes and eradicates disease in models of MLL-rearranged leukemia","volume":"36","author":"Krivtsov","year":"2019","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.hoc.2026.03.001_bib54","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/nchembio.773","article-title":"Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia","volume":"8","author":"Grembecka","year":"2012","journal-title":"Nat Chem Biol"},{"issue":"1","key":"10.1016\/j.hoc.2026.03.001_bib55","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1200\/JCO.24.00826","article-title":"Menin inhibition with revumenib for KMT2A-Rearranged relapsed or refractory acute leukemia (AUGMENT-101)","volume":"43","author":"Issa","year":"2025","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2026.03.001_bib56","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.3109\/10428194.2011.559668","article-title":"Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases","volume":"52","author":"Raponi","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.hoc.2026.03.001_bib57","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/pbc.25410","article-title":"Characterization of CD22 expression in acute lymphoblastic leukemia","volume":"62","author":"Shah","year":"2015","journal-title":"Pediatr Blood Cancer"},{"issue":"36","key":"10.1016\/j.hoc.2026.03.001_bib58","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1200\/JCO.2016.67.3301","article-title":"Phase I\/phase II study of blinatumomab in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"34","author":"von Stackelberg","year":"2016","journal-title":"J Clin Oncol"},{"issue":"9757","key":"10.1016\/j.hoc.2026.03.001_bib59","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1016\/S0140-6736(10)62002-8","article-title":"Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial","volume":"376","author":"Parker","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.hoc.2026.03.001_bib60","volume":"134","author":"Brown","year":"2019","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.hoc.2026.03.001_bib61","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1200\/JCO.22.02200","article-title":"Children\u2019s Oncology Group AALL1331: phase III trial of blinatumomab in children, adolescents, and young adults with low-risk B-Cell ALL in first relapse","volume":"41","author":"Hogan","year":"2023","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2026.03.001_bib62","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.hoc.2026.03.001_bib63","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa2312948","article-title":"Blinatumomab for MRD-negative acute lymphoblastic leukemia in adults","volume":"391","author":"Litzow","year":"2024","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.hoc.2026.03.001_bib64","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1200\/JCO-25-01806","article-title":"Sustained benefit of blinatumomab in infants with KMT2A-Rearranged ALL: long-term outcomes, toxicity, and pharmacokinetics","volume":"44","author":"Vieira Martins","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2026.03.001_bib65","first-page":"1","article-title":"Cutting to the front of the line: immunotherapy for childhood acute lymphoblastic leukemia","volume":"40","author":"McNeer","year":"2020","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"9","key":"10.1016\/j.hoc.2026.03.001_bib66","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2411680","article-title":"Blinatumomab in standard-risk B-Cell acute lymphoblastic leukemia in children","volume":"392","author":"Gupta","year":"2025","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.hoc.2026.03.001_bib67","doi-asserted-by":"crossref","first-page":"4230","DOI":"10.1158\/1078-0432.CCR-25-1034","article-title":"FDA approval summary: Blinatumomab for the treatment of B-Cell precursor acute lymphoblastic leukemia in the consolidation phase of multiphase chemotherapy","volume":"31","author":"Rabik","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.hoc.2026.03.001_bib68","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.hoc.2026.03.001_bib69","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/s41375-018-0265-z","article-title":"Inotuzumab ozogamicin in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"33","author":"Bhojwani","year":"2019","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.hoc.2026.03.001_bib70","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1038\/s41375-022-01576-3","article-title":"Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial","volume":"36","author":"Pennesi","year":"2022","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.hoc.2026.03.001_bib71","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1200\/JCO.21.01693","article-title":"Phase II trial of inotuzumab ozogamicin in children and adolescents with relapsed or refractory B-Cell acute lymphoblastic leukemia: children\u2019s oncology group protocol AALL1621","volume":"40","author":"O'Brien","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2026.03.001_bib72","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1182\/blood-2019-128977","article-title":"A phase 2 trial of inotuzumab ozogamicin (InO) in children and young adults with relapsed or refractory (R\/R) CD221 B-Acute lymphoblastic leukemia (B-ALL): results from children\u2019s oncology group protocol AALL1621","volume":"134","author":"O\u2019Brien","year":"2019","journal-title":"Blood"},{"issue":"95","key":"10.1016\/j.hoc.2026.03.001_bib73","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002842","article-title":"T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci Transl Med"},{"issue":"16","key":"10.1016\/j.hoc.2026.03.001_bib74","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.hoc.2026.03.001_bib75","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.hoc.2026.03.001_bib76","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.hoc.2026.03.001_bib77","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1182\/blood-2016-01-694356","article-title":"Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy","volume":"128","author":"Bhoj","year":"2016","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.hoc.2026.03.001_bib78","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1182\/bloodadvances.2019000692","article-title":"CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy","volume":"3","author":"Pillai","year":"2019","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.hoc.2026.03.001_bib79","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nm.4441","article-title":"CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","volume":"24","author":"Fry","year":"2018","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.hoc.2026.03.001_bib80","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1182\/hematology.2019000018","article-title":"Mechanisms of and approaches to overcoming resistance to immunotherapy","volume":"2019","author":"Schultz","year":"2019","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2026.03.001_bib81","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-113126","article-title":"Early clinical experience of CD19 x CD22 dual specific CAR T cells for enhanced anti-leukemic targeting of acute lymphoblastic leukemia","volume":"132","author":"Gardner","year":"2018","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2026.03.001_bib82","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1182\/blood-2018-99-117445","article-title":"Phase 1 study of CD19\/CD22 bispecific chimeric antigen receptor (CAR) therapy in children and young adults with b cell acute lymphoblastic leukemia (ALL)","volume":"132","author":"Schultz","year":"2018","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2026.03.001_bib83","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1182\/blood-2018-99-118616","article-title":"Simultaneous targeting of CD19 and CD22: phase I study of AUTO3, a bicistronic chimeric antigen receptor (CAR) T-Cell therapy, in pediatric patients with relapsed\/refractory B-Cell acute lymphoblastic leukemia (r\/r B-ALL): amelia study","volume":"132","author":"Amrolia","year":"2018","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.hoc.2026.03.001_bib84","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1200\/JCO.2011.40.8724","article-title":"Pilot study of nelarabine in combination with intensive chemotherapy in high-risk T-cell acute lymphoblastic leukemia: a report from the Children\u2019s Oncology Group","volume":"30","author":"Dunsmore","year":"2012","journal-title":"J Clin Oncol"},{"issue":"S2","key":"10.1016\/j.hoc.2026.03.001_bib85","article-title":"Cog AALL0434: a randomized trial testing nelarabine in newly diagnosed T-cell malignancy","volume":"65","author":"Dunsmore","year":"2018","journal-title":"Pediatr Blood Cancer"},{"issue":"9","key":"10.1016\/j.hoc.2026.03.001_bib86","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1182\/blood.V84.9.3122.3122","article-title":"Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86","volume":"84","author":"Reiter","year":"1994","journal-title":"Blood"},{"issue":"29","key":"10.1016\/j.hoc.2026.03.001_bib87","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1200\/JCO.2018.77.7250","article-title":"Improved survival for children and young adults with T-Lineage acute lymphoblastic leukemia: results from the Children\u2019s Oncology Group AALL0434 methotrexate randomization","volume":"36","author":"Winter","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2026.03.001_bib88","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00280-005-0135-z","article-title":"Bortezomib interactions with chemotherapy agents in acute leukemia in vitro","volume":"58","author":"Horton","year":"2006","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"10.1016\/j.hoc.2026.03.001_bib89","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/bjh.15919","article-title":"Bortezomib reinduction chemotherapy in high-risk ALL in first relapse: a report from the Children\u2019s Oncology Group","volume":"186","author":"Horton","year":"2019","journal-title":"Br J Haematol"},{"issue":"19","key":"10.1016\/j.hoc.2026.03.001_bib90","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1200\/JCO.21.02678","article-title":"Children\u2019s Oncology Group trial AALL1231: a phase III clinical trial testing bortezomib in newly diagnosed T-Cell acute lymphoblastic leukemia and lymphoma","volume":"40","author":"Teachey","year":"2022","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2026.03.001_bib91","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1182\/blood-2017-07-794214","article-title":"Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia","volume":"131","author":"Bride","year":"2018","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.hoc.2026.03.001_bib92","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1182\/blood.2024024493","article-title":"Daratumumab in pediatric relapsed\/refractory acute lymphoblastic leukemia or lymphoblastic lymphoma: the DELPHINUS study","volume":"144","author":"Bhatla","year":"2024","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2026.03.001_bib93","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1182\/blood.2025028387","article-title":"Phase 1\/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed\/refractory T-cell malignancies","volume":"146","author":"Ghobadi","year":"2025","journal-title":"Blood"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858826000195?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858826000195?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T04:56:58Z","timestamp":1781153818000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858826000195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":93,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0889858826000195"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2026.03.001","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Updates in Childhood Acute Lymphoblastic Leukemia","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2026.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}